Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
SURITAL (thiamylal sodium) is a barbiturate injectable anesthetic approved in 1954 for intravenous administration. It was historically used for induction of general anesthesia and sedation in surgical and procedural settings. The drug acts as a central nervous system depressant via barbiturate mechanism.
With LOE approaching and minimal linked job activity, the brand team is likely in maintenance mode with small team structure focused on legacy support rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on SURITAL offers limited career growth given the product's LOE status and zero linked job openings; opportunities are restricted to legacy portfolio management and compliance roles. This assignment is best suited for professionals seeking portfolio management experience on mature/declining products rather than career acceleration.
Worked on SURITAL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.